Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 8
Encontrada(s) 1 página(s)

Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Maternal proteomic profiling reveals alterations in lipid metabolism in late-onset fetal growth restriction

  • Paules, C.
  • Youssef, L.
  • Miranda, J.
  • Crovetto, F.
  • Estanyol, J.M.
  • Fernandez, G.
  • Crispi, F.
  • Gratacós, E.
Fetal growth restriction defined as the failure to achieve the fetal genetic growth potential is a major cause of perinatal morbidity and mortality. The role of maternal adaptations to placental insufficiency in this disorder is still not fully understood. We aimed to investigate the biological processes and protein–protein interactions involved in late-onset fetal growth restriction in particular. We applied 2D nano LC–MS/MS proteomics analysis on maternal blood samples collected at the time of delivery from 5 singleton pregnancies with late-onset fetal growth restriction and 5 uncomplicated pregnancies. Data were analyzed using R package “limma” and Ingenuity Pathway Analysis. 25 proteins showed significant changes in their relative abundance in late-onset fetal growth restriction (p value < 0.05). Direct protein–protein interactions network demonstrated that Neurogenic locus notch homolog protein 1 (NOTCH1) was the most significant putative upstream regulator of the observed profile. Gene ontology analysis of these proteins revealed the involvement of 14 canonical pathways. The most significant biological processes were efflux of cholesterol, efflux of phospholipids, adhesion of blood cells, fatty acid metabolism and dyslipidemia. Future studies are warranted to validate the potential role of the detected altered proteins as potential therapeutic targets in the late-onset form of fetal growth restriction.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Up-regulation of HDACs, a harbinger of uraemic endothelial dysfunction, is prevented by defibrotide

  • Palomo, Marta|||0000-0002-3261-6577
  • Vera, Manuel|||0000-0001-9937-7235
  • Martín, Susana
  • Torramadé-Moix, S.
  • Martínez Sánchez, Julia
  • Belen Moreno, A.
  • Carreras, Enric|||0000-0002-3134-9964
  • Escolar, Ginès
  • Cases Amenós, Aleix|||0000-0002-6962-8184
  • Diaz-Ricart, Maribel|||0000-0003-1122-0052
Endothelial dysfunction is an earlier contributor to the development of atherosclerosis in chronic kidney disease (CKD), in which the role of epigenetic triggers cannot be ruled out. Endothelial protective strategies, such as defibrotide (DF), may be useful in this scenario. We evaluated changes induced by CKD on endothelial cell proteome and explored the effect of DF and the mechanisms involved. Human umbilical cord vein endothelial cells were exposed to sera from healthy donors (n = 20) and patients with end-stage renal disease on haemodialysis (n = 20). Differential protein expression was investigated by using a proteomic approach, Western blot and immunofluorescence. HDAC1 and HDAC2 overexpression was detected. Increased HDAC1 expression occurred at both cytoplasm and nucleus. These effects were dose-dependently inhibited by DF. Both the HDACs inhibitor trichostatin A and DF prevented the up-regulation of the endothelial dysfunction markers induced by the uraemic milieu: intercellular adhesion molecule-1, surface Toll-like receptor-4, von Willebrand Factor and reactive oxygen species. Moreover, DF down-regulated HDACs expression through the PI3/AKT signalling pathway. HDACs appear as key modulators of the CKD-induced endothelial dysfunction as specific blockade by trichostatin A or by DF prevents endothelial dysfunction responses to the CKD insult. Moreover, DF exerts its endothelial protective effect by inhibiting HDAC up-regulation likely through PI3K/AKT.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Endothelial damage, inflammation and immunity in chronic kidney disease

  • Diaz-Ricart, Maribel|||0000-0003-1122-0052
  • Torramade-Moix, S.
  • Pascual, G.
  • Palomo, Marta|||0000-0002-3261-6577
  • Moreno-Castaño, Ana Belén|||0000-0003-0338-7514
  • Martínez Sánchez, Julia
  • Vera, M.
  • Cases Amenós, Aleix|||0000-0002-6962-8184
  • Escolar, Ginès
Chronic kidney disease (CKD) patients have an accelerated atherosclerosis, increased risk of thrombotic-ischemic complications, and excessive mortality rates when compared with the general population. There is also evidence of an endothelial damage in which the proinflammatory state, the enhanced oxidative stress, or the accumulation of toxins due to their reduced renal clearance in uremia play a role. Further, there is evidence that uremic endothelial cells are both involved in and victims of the activation of the innate immunity. Uremic endothelial cells produce danger associated molecular patterns (DAMPS), which by binding to specific pattern recognition receptors expressed in multiple cells, including endothelial cells, induce the expression of adhesion molecules, the production of proinflammatory cytokines and an enhanced production of reactive oxygen species in endothelial cells, which constitute a link between immunity and inflammation. The connection between endothelial damage, inflammation and defective immunity in uremia will be reviewed here.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Defibrotide inhibits donor leucocyte-endothelial interactions and protects against acute graft-versus-host disease

  • García-Bernal, D.
  • Palomo, Marta|||0000-0002-3261-6577
  • Martínez, C. M.
  • Millán-Rivero, J. E.
  • García-Guillén, A. I.
  • Blanquer, M.
  • Diaz-Ricart, Maribel|||0000-0003-1122-0052
  • Sackstein, Robert
  • Carreras, Enric|||0000-0002-3134-9964
  • Moraleda, J. M.
Allogeneic hematopoietic stem cell transplantation (allo-HCT) is an effective therapy for the treatment of high-risk haematological malignant disorders and other life-threatening haematological and genetic diseases. Acute graft-versus-host disease (aGvHD) remains the most frequent cause of non-relapse mortality following allo-HCT and limits its extensive clinical application. Current pharmacologic agents used for prophylaxis and treatment of aGvHD are not uniformly successful and have serious secondary side effects. Therefore, more effective and safe prophylaxis and therapy for aGvHD are an unmet clinical need. Defibrotide is a multi-target drug successfully employed for prophylaxis and treatment of veno-occlusive disease/sinusoidal obstruction syndrome. Recent preliminary clinical data have suggested some efficacy of defibrotide in the prevention of aGvHD after allo-HCT. Using a fully MHC-mismatched murine model of allo-HCT, we report here that defibrotide, either in prophylaxis or treatment, is effective in preventing T cell and neutrophil infiltration and aGvHD-associated tissue injury, thus reducing aGvHD incidence and severity, with significantly improved survival after allo-HCT. Moreover, we performed in vitro mechanistic studies using human cells revealing that defibrotide inhibits leucocyte-endothelial interactions by down-regulating expression of key endothelial adhesion molecules involved in leucocyte trafficking. Together, these findings provide evidence that defibrotide may represent an effective and safe clinical alternative for both prophylaxis and treatment of aGvHD after allo-HCT, paving the way for new therapeutic approaches.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Acute Graft-vs.-Host Disease-Associated Endothelial Activation in vitro Is Prevented by Defibrotide

  • Martínez Sánchez, Julia
  • Hamelmann, H.
  • Palomo, Marta|||0000-0002-3261-6577
  • Mir, Enrique
  • Moreno-Castaño, Ana Belén|||0000-0003-0338-7514
  • Torramade, S.
  • Rovira, M.
  • Escolar, Ginès
  • Cordes, Steffen
  • Kalupa, Martina
  • Mertlitz, S.
  • Riesner, K.
  • Carreras, Enric|||0000-0002-3134-9964
  • Penack, Olaf|||0000-0003-4876-802X
  • Diaz-Ricart, Maribel|||0000-0003-1122-0052
Angiogenesis and endothelial activation and dysfunction have been associated with acute graft-vs.-host disease (aGVHD), pointing to the endothelium as a potential target for pharmacological intervention. Defibrotide (DF) is a drug with an endothelium-protective effect that has been approved for the treatment of veno-occlusive disease/sinusoidal obstruction syndrome after allogeneic hematopoietic cell transplantation. Clinical data suggest that DF also reduces the incidence of aGVHD; however, the mechanisms of DF-mediated aGVHD regulation have not been examined. To investigate possible DF-mediated prophylactic and therapeutic mechanisms in aGVHD, we performed in vitro studies using endothelial cell (EC) lines. We found that DF significantly and dose-dependently suppressed EC proliferation and notably reduced their ability to form vascular tubes in Matrigel. To explore whether DF administered prophylactically or therapeutically has a significant effect on aGVHD endothelial dysfunction, ECs were exposed to media containing sera from patients with aGVHD (n = 22) in the absence or presence of DF and from patients that did not develop aGVHD (n = 13). ECs upregulated adhesion molecules (vascular cell adhesion molecule 1, intercellular adhesion molecule 1), the adherence junction protein VE-cadherin, von Willebrand factor (VWF), and Akt phosphorylation in response to aGVHD sera. These responses were suppressed upon treatment with DF. In summary, DF inhibits vascular angiogenesis and endothelial activation induced by sera from aGVHD patients. Our results support the view that DF has notable positive effects on endothelial biology during aGVHD.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Normalization of blood clotting characteristics using prothrombin complex concentrate, fibrinogen and FXIII in an albumin based fluid, experimental studies in thromboelastometry

  • Koller, Tobias|||0000-0002-6247-0193
  • Kinast, Nadia
  • Guilarte Castellanos, Andres
  • Pérez García, Sergio|||0000-0003-4242-0858
  • Paniagua, Pilar|||0000-0002-0215-1561
  • Vintro, Xavi León|||0000-0002-9673-5786
  • Arranz, Jose Mateo
  • Vilalta, Noelia|||0000-0002-3961-3563
  • García, Ma. Victòria Moral
  • Moreno-Castaño, Ana Belén|||0000-0003-0338-7514
  • Aznar-Salatti, Jose
  • Albaladejo, Gines Escolar
  • Diaz-Ricart, Maribel|||0000-0003-1122-0052
Colloid fluids supplemented with adequate combinations of coagulation factor concentrates with the capability to restore coagulation could be a desirable future treatment component in massive transfusion. Starting from a coagulation factor and blood cell-free albumin solution we added Prothrombin Complex Concentrate, Fibrinogen Concentrate and Factor XIII in different combinations and concentrations to analyze their properties to restore thromboelastometry parameters without the use of plasma. Further analysis under the presence of platelets was performed for comparability to whole blood conditions. Albumin solutions enriched with Fibrinogen Concentrate, Factor XIII and Prothrombin Complex Concentrate at optimized concentrations show restoring coagulation potential. Prothrombin Complex Concentrate showed sufficient thrombin formation for inducing fibrinogen polymerization. The combination of Prothrombin Complex Concentrate and Fibrinogen Concentrate led to the formation of a stable in vitro fibrin clot. Fibrinogen and Factor XIII showed excellent capacity to improve fibrin clot firmness expressed as Amplitude at 10 min and Maximal Clot Firmness. Fibrinogen alone, or in combination with Factor XIII, was able to restore normal Amplitude at 10 min and Maximal Clot Firmness values. In the presence of platelets, the thromboelastometry surrogate parameter for thrombin generation (Clotting Time) improves and normalizes when compared to whole blood. Combinations of coagulation factor concentrates suspended in albumin solutions can restore thromboelastometry parameters in the absence of plasma. This kind of artificial colloid fluids with coagulation-restoring characteristics might offer new treatment alternatives for massive transfusion. Study registered at the institutional ethic committee "Institut de Recerca, Hospital Santa Creu i Sant Pau, with protocol number IIBSP-CFC-2013-165.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

The Interplay between Pathophysiological Pathways in Early-Onset Severe Preeclampsia Unveiled by Metabolomics

  • Youssef, Lina|||0000-0002-0554-5507
  • Crovetto, Francesca|||0000-0003-0140-7411
  • Simoes, Rui Vasco|||0000-0001-7574-4723
  • Miranda, Jezid|||0000-0003-0372-8374
  • Paules, Cristina|||0000-0001-6795-0367
  • Blasco Pelicano, Miquel|||0000-0003-0789-7992
  • Palomo, Marta|||0000-0002-3261-6577
  • García Calderó, Héctor|||0000-0002-8801-6394
  • Tura-Ceide, Olga|||0000-0003-4334-9790
  • Dantas, A. P|||0000-0001-8514-4094
  • Hernández-Gea, Virginia|||0000-0001-7937-984X
  • Herrero, Pol|||0000-0002-8746-7214
  • Canela, Núria|||0000-0003-0261-2396
  • Campistol Plana, Josep M.|||0000-0002-6841-1119
  • Garcia Pagan, Joan Carles
  • Diaz-Ricart, Maribel|||0000-0003-1122-0052
  • Gratacós, Eduard|||0000-0002-7405-7224
  • Crispi, Fatima|||0000-0002-7422-5240
Introduction: Preeclampsia is a multi-system disorder unique to pregnancy responsible for a great part of maternal and perinatal morbidity and mortality. The precise pathogenesis of this complex disorder is still unrevealed. Methods: We examined the pathophysiological pathways involved in early-onset preeclampsia, a specific subgroup representing its most severe presentation, using LC-MS/MS metabolomic analysis based on multi-level extraction of lipids and small metabolites from maternal blood samples, collected at the time of diagnosis from 14 preeclamptic and six matched healthy pregnancies. Statistical analysis comprised multivariate and univariate approaches with the application of over representation analysis to identify differential pathways. Results: A clear difference between preeclamptic and control pregnancies was observed in principal component analysis. Supervised multivariate analysis using orthogonal partial least square discriminant analysis provided a robust model with goodness of fit (R X = 0.91, p = 0.002) and predictive ability (Q Y = 0.72, p < 0.001). Finally, univariate analysis followed by 5% false discovery rate correction indicated 82 metabolites significantly altered, corresponding to six overrepresented pathways: (1) aminoacyl-tRNA biosynthesis; (2) arginine biosynthesis; (3) alanine, aspartate and glutamate metabolism; (4) D-glutamine and D-glutamate metabolism; (5) arginine and proline metabolism; and (6) histidine metabolism. Conclusion: Metabolomic analysis focusing specifically on the early-onset severe form of preeclampsia reveals the interplay between pathophysiological pathways involved in this form. Future studies are required to explore new therapeutic approaches targeting these altered metabolic pathways in early-onset preeclampsia.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Complement and coagulation cascades activation is the main pathophysiological pathway in early-onset severe preeclampsia revealed by maternal proteomics

  • Youssef, Lina|||0000-0002-0554-5507
  • Miranda, Jezid|||0000-0003-0372-8374
  • Blasco Pelicano, Miquel|||0000-0003-0789-7992
  • Paules, Cristina|||0000-0001-6795-0367
  • Crovetto, Francesca|||0000-0003-0140-7411
  • Palomo, Marta|||0000-0002-3261-6577
  • Torramade Moix, Sergi
  • García Calderó, Héctor|||0000-0002-8801-6394
  • Tura-Ceide, Olga|||0000-0003-4334-9790
  • Dantas, A. P.|||0000-0001-8514-4094
  • Hernández-Gea, Virginia|||0000-0001-7937-984X
  • Herrero, Pol|||0000-0002-8746-7214
  • Canela, Núria|||0000-0003-0261-2396
  • Campistol Plana, Josep M.|||0000-0002-6841-1119
  • Garcia Pagan, Joan Carles
  • Diaz-Ricart, Maribel|||0000-0003-1122-0052
  • Gratacós, Eduard|||0000-0002-7405-7224
  • Crispi, Fatima|||0000-0002-7422-5240
Preeclampsia is a pregnancy-specific multisystem disorder and a leading cause of maternal and perinatal morbidity and mortality. The exact pathogenesis of this multifactorial disease remains poorly defined. We applied proteomics analysis on maternal blood samples collected from 14 singleton pregnancies with early-onset severe preeclampsia and 6 uncomplicated pregnancies to investigate the pathophysiological pathways involved in this specific subgroup of preeclampsia. Maternal blood was drawn at diagnosis for cases and at matched gestational age for controls. LC-MS/MS proteomics analysis was conducted, and data were analyzed by multivariate and univariate statistical approaches with the identification of differential pathways by exploring the global human protein-protein interaction network. The unsupervised multivariate analysis (the principal component analysis) showed a clear difference between preeclamptic and uncomplicated pregnancies. The supervised multivariate analysis using orthogonal partial least square discriminant analysis resulted in a model with goodness of fit (RX = 0.99, p < 0.001) and a strong predictive ability (QY = 0.8, p < 0.001). By univariate analysis, we found 17 proteins statistically different after 5% FDR correction (q-value < 0.05). Pathway enrichment analysis revealed 5 significantly enriched pathways whereby the activation of the complement and coagulation cascades was on top (p = 3.17e-07). To validate these results, we assessed the deposits of C5b-9 complement complex and on endothelial cells that were exposed to activated plasma from an independent set of 4 cases of early-onset severe preeclampsia and 4 uncomplicated pregnancies. C5b-9 and Von Willbrand factor deposits were significantly higher in early-onset severe preeclampsia. Future studies are warranted to investigate potential therapeutic targets for early-onset severe preeclampsia within the complement and coagulation pathway.